TORNTPHARM Torrent Pharmaceuticals Q1 FY26 results (Apr–Jun 2025) and concall
Management summary
- Torrent Pharma started FY26 with steady double-digit growth led by its core branded markets in India and Brazil.
- While Germany faced temporary supply disruptions from a third-party partner, the US business showed recovery with strong constant currency growth and narrowing losses.
- Management expressed high confidence in maintaining a 32.9% margin floor for the remainder of the fiscal year.
Source: Inve concall analysis and management guidance record.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|
| Revenue | 2,377 | 2,433 | 2,616 |
| EBITDA | 887 | 868 | 979 |
| Net profit | 485 | 474 | 551 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Margin
Adjusted EBITDA Margin Margin · FY26 · High confidence 32.9%
Headcount
India Field Force (MRs) Headcount · by end of FY26 · High confidence 6,900-7,000
From 6,400 today
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Germany Supply Disruption Partial
Neha, unfortunately, I won't make a prediction, at least a couple of quarters... we are kind of a little bit hostage to the situation in the sense it's not within our direct control.
Reveals that 75% of the Germany business relies on third-party products, creating a significant external dependency risk.
Asked by Neha Manpuria
US Profitability Timeline Direct
Yes, Neha, it's still not profitable. It'll take some while before we get into the profitable zone post R&D.
Confirms that despite 16% CC growth, the US segment is still a drag on consolidated net profit due to R&D costs.
Asked by Neha Manpuria
Unlock risks & concerns, Q2 FY26 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 3 risks, concerns & management red flags
- Watchlist triggers for Q2 FY26
- +3 more guidance targets & verbatim management quotes
- +1 more analyst Q&A exchange & evasion checks
- Full section-by-section call narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





